June 22, 2020 / 1:20 PM / 15 days ago

Gilead to test inhaled version of remdesivir on COVID-19 patients in August

June 22 (Reuters) - Gilead Sciences Inc said on Monday that it plans to begin clinical trials of an inhaled version of its antiviral treatment remdesivir for COVID-19 patients in August.

The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals, the company said in a statement. (bit.ly/3eqpEJ9) (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below